Clinical research on the safety and efficacy of iAPDA-DC/CTL treatment on malignant tumor of digestive system (mainly in biliary system and pancreas)

clinical research on the safety and efficacy of new cellular immunotherapy on advanced panreatic cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006946

Enrollment

Unknown

Registered

2015-08-20

Start date

2015-08-18

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

control group :Gemcitabine

treatment group :iAPA-DC/CTL+Gemcitabine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Advanced Pancreatic cancer patients with Histological pathology confirmation; 2. Both gender, aged 18-70 year-old; 3. Bone marrow functioned well; 4. Renal function normal; 5. Liver function normal; 6. patients are voluntary, and willing to sign informed consent; 7. expected lifetime was at least more than 3 months.

Exclusion criteria

Exclusion criteria: 1. With acute inflammation; 2. Accompanied with primary malignant tumor other than pancreas; 3. with autoimmune disease; 4. using corticosteroid or other suppress immune hormone treatment; 5. had transplant operation of vital organs; 6. active hepatitis; 7. HIV positive; 8. dysfunction in blood coagulation; 9. serious diseases in circulatory and respiratory systems; 10. pregnancy or breast-feeding women.

Design outcomes

Primary

Measure	Time frame
6 months survival rate;	—

Secondary

Measure	Time frame
Overall Survival;Progression-Free Survival;Objective Response Rate;Quality of life;	—

Countries

China

Contacts

Public ContactZhaoshen Li

zhaoshenlismmu@gmail.com+86 021-25070552

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026